Uncategorized

Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico

Published

4 days ago

on

After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version